$2.98
2.41% today
Nasdaq, Feb 05, 04:18 pm CET
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Geron Corporation Stock price

$2.91
-0.52 15.16% 1M
-1.60 35.48% 6M
-0.63 17.80% YTD
+1.09 59.89% 1Y
+1.90 188.12% 3Y
+1.61 123.85% 5Y
-0.09 3.00% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.06 2.11%
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Key metrics

Market capitalization $1.76b
Enterprise Value $1.50b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 51.04
P/S ratio (TTM) P/S ratio 59.67
P/B ratio (TTM) P/B ratio 6.00
Revenue growth (TTM) Revenue growth 9,199.68%
Revenue (TTM) Revenue $29.48m
EBIT (operating result TTM) EBIT $-207.97m
Free Cash Flow (TTM) Free Cash Flow $-216.50m
Cash position $341.63m
EPS (TTM) EPS $-0.32
P/E forward negative
P/S forward 19.37
EV/Sales forward 16.57
Short interest 12.26%
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

Buy
100%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
29 29
9,113% 9,113%
100%
- Direct Costs 1.62 1.62
-
5%
28 28
-
95%
- Selling and Administrative Expenses 121 121
104% 104%
412%
- Research and Development Expense 113 113
6% 6%
384%
-207 -207
15% 15%
-702%
- Depreciation and Amortization 1.15 1.15
13% 13%
4%
EBIT (Operating Income) EBIT -208 -208
15% 15%
-705%
Net Profit -201 -201
15% 15%
-682%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Positive
Seeking Alpha
2 days ago
GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns, GERN still has many years of sales ahead unencumbered by generic competition. EU approval of Rytelo for lower-risk myelodysplastic syndromes seems likely in H1'25, providing a near-term catalyst beyond u...
Neutral
Business Wire
2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will...
Neutral
Business Wire
15 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock, consisting of stock options to purchase an aggregate of 208,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 104,000 shares of...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO John Scarlett
Employees 141
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today